Tonix Pharmaceuticals (TNXP) Trading Down 2.8%
Shares of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) traded down 2.8% during mid-day trading on Monday . The stock traded as low as $2.81 and last traded at $2.80. 1,544 shares were traded during trading, a decline of 100% from the average session volume of 1,534,396 shares. The stock had previously closed at $2.88.
The firm has a market capitalization of $4.40 million, a PE ratio of -0.10 and a beta of 1.85.
Several institutional investors and hedge funds have recently added to or reduced their stakes in TNXP. Citigroup Inc. acquired a new stake in shares of Tonix Pharmaceuticals during the 4th quarter worth $34,000. CVI Holdings LLC bought a new stake in shares of Tonix Pharmaceuticals during the 4th quarter worth $36,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Tonix Pharmaceuticals during the 4th quarter worth $38,000. 34.30% of the stock is currently owned by institutional investors.
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population.
Featured Story: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.